The authors argued that both Ang II infusion and L-NAME treatment upregulated renal ACE 1.5- to 2-fold, thus enhancing local Ang II generation and sodium transporter activation and subsequently leading to hypertension via a reduction in natriuresis. The gene discussed is ACE; the disease is Hypertension.